Outcomes of third line chemotherapy for recurrent and persistent cervical cancer

被引：0
|
作者：
Manders, D. B. [1 ]
Purinton, S. C. [1 ]
Lea, J. S. [1 ]
Miller, D. S. [1 ]
Kehoe, S. M. [1 ]
Richardson, D. L. [1 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
GYNECOLOGIC ONCOLOGY | 2011年 / 123卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2011.07.073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：442 / 443
页数：2
相关论文
共 50 条
  • [21] Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer
    Mansi, Laura
    Demarchi, Martin
    Bazan, Fernando
    Delroeux, Delphine
    Chaigneau, Loic
    Thiery-Vuillemin, Antoine
    Bernhard, Sandrine
    Lakkis, Zaehr
    Nerich, Virginie
    Pivot, Xavier
    Kalbacher, Elsa
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (02) : 261 - 267
  • [22] Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer
    Lin, Ying-tao
    Wang, Chang
    He, Xiao-yan
    Yao, Qi-min
    Chen, Jian
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [23] Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy
    Ittiamornlert, Pornprom
    Ruengkhachorn, Irene
    [J]. BMC CANCER, 2019, 19 (1)
  • [24] Chemotherapy for metastatic and recurrent cervical cancer
    Scatchard, Kate
    Forrest, Jennifer L.
    Flubacher, Maxine
    Cornes, Paul
    Williams, Chris
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (10):
  • [25] Chemotherapy for recurrent and metastatic cervical cancer
    Tao, Xia
    Hu, Wei
    Ramirez, Pedro T.
    Kavanagh, John J.
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 110 (03) : S67 - S71
  • [26] Chemotherapy for advanced or recurrent cervical cancer
    Kamura, Toshiharu
    Ushijima, Kimio
    [J]. TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2013, 52 (02): : 161 - 164
  • [27] Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy
    Pornprom Ittiamornlert
    Irene Ruengkhachorn
    [J]. BMC Cancer, 19
  • [28] Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
    Vergote, Ignace
    Gonzalez-Martin, Antonio
    Fujiwara, Keiichi
    Kalbacher, Elsa
    Bagameri, Andrea
    Ghamande, Sharad
    Lee, Jung-Yun
    Banerjee, Susana
    Maluf, Fernando Cotait
    Lorusso, Domenica
    Yonemori, Kan
    Van Nieuwenhuysen, Els
    Manso, Luis
    Woelber, Linn
    Westermann, Anneke
    Covens, Allan
    Hasegawa, Kosei
    Kim, Byoung-Gie
    Raimondo, Miriam
    Bjurberg, Maria
    Cruz, Felipe Melo
    Angelergues, Antoine
    Cibula, David
    Barraclough, Lisa
    Oaknin, Ana
    Gennigens, Christine
    Nicacio, Leo
    Teng, Melinda Siew Leng
    Whalley, Elizabeth
    Soumaoro, Ibrahima
    Slomovitz, Brian M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (01): : 44 - 55
  • [29] Pelvic Exenteration for Recurrent and Persistent Cervical Cancer
    Li Lei
    Ma ShuiQing
    Tan XianJie
    Zhong Sen
    Wu Ming
    Department of Obstetrics and Gynecology Peking Union Medical College Hospital Peking Union Medical College Chinese Academy of Medical Sciences Beijing China
    [J]. 中华医学杂志(英文版), 2018, (13) : 1541 - 1548
  • [30] Pelvic Exenteration for Recurrent and Persistent Cervical Cancer
    Li, Lei
    Ma, Shui-Qing
    Tan, Xian-Jie
    Zhong, Sen
    Wu, Ming
    [J]. CHINESE MEDICAL JOURNAL, 2018, 131 (13) : 1541 - 1548
12345